Weberpals (2021)
Advanced non-small cell lung cancer
Oncology • Ehr Data • US
Study Metrics
Covariates
441
PICO Comparisons
1
Quality Indicators
Transparency
High
DAG Usage
No
QBA Performed
No
Study Information
| First Author: | Weberpals |
| Publication Year: | 2021 |
| DOI: | https://doi.org/10.1097/ede.0000000000001338 |
| Preprint: | No preprint |
Institution & Funding
| Institutions: | Roche Innovation Center Munich (industry), xValue GmbH (industry), F. Hoffmann-La Roche Ltd (industry), German Research Center for Environmental Health - Helmholtz Center Munich (academia), Technical University of Munich (academia) |
| Funding: | Delcared: Private |
| Funding Institutions: | This work was funded by Roche as part of the main authors (J.W.) postdoctoral fellowship program (RPF-ID: 498). |
Study Context
| Disease: | Advanced non-small cell lung cancer |
| Disease Category: | Oncology |
| Data Type: | Electronic Health Records |
| Number of Data Sources: | 1 |
| Geography: | US |
| Eligible Sample: | 781.0 |
| Number of Treatments: | 2 |
Analytical Methods
| Missing Data Method: | Median imputation and assigning a missing-indicator category |
| Matching Method: | 1:1 PS matching |
| Analysis Method: | Cox PH |
Quality Methods
Directed Acyclic Graph (DAG)
Not Used
Quantitative Bias Analysis (QBA)
Not Performed
Target Trial Information
| Target Trial Name: | PRONOUNCE |
| Registration Number: | NCT00948675 |
| Target Trial DOI: | https://doi.org/10.1097/jto.0000000000000366 |
TTE vs RCT Comparisons
Detailed comparison between Target Trial Emulation results and corresponding Randomized Controlled Trial outcomes.
Overall survival
PRONOUNCE
HR
Efficacy
Population
patients with advanced nonsquamous non-small-cell lung cancer
Intervention
carboplatin/pemetrexed followed by pemetrexed maintenance
Comparison
bevacizumab/carboplatin/paclitaxel followed by bevacizumab maintenance
Outcome
Overall survival
RCT Result
1.07
95% CI: [0.83, 1.36]
vs
TTE Result
1.09
95% CI: [0.87, 1.37]
Concordance Assessment
Confidence Interval Overlap:
Yes
CIs overlap, suggesting concordance
CIs overlap, suggesting concordance
Direction Agreement:
Same Direction
Both point to similar conclusion
Both point to similar conclusion
Transparency Indicators
Protocol Registration
Available
Data Sharing
Not Available
Code Sharing
Available
Overall Transparency Score:
High Transparency - This study meets good transparency standards.
Conflicts & Funding
| Conflicts of Interest: | Declared: Financial |
| COI Institutions: | Roche, xValue, Roche Diagnostics GmbH, Cellarity Inc. |
| Funding Source: | Delcared: Private |
| Funding Institutions: | This work was funded by Roche as part of the main authors (J.W.) postdoctoral fellowship program (RPF-ID: 498). |